Therapeutics

Small Mobile Cells

Universal, Low-Immunogenicity Regenerative Cells

• Under 5 microns in size and present in peripheral blood.
• Virtually no HLA markers, making them effectively universal transplant material with minimal immune rejection risk.
• Demonstrated reversal of fibrotic conditions, notably COPD and pulmonary fibrosis.
• Shown excellent results for neurodegenerative conditions and post-stroke recovery.
• Transportable between clinics, enabling wider clinical deployment.
• Used clinically for longevity and sports-injury recovery with strong subjective benefits.
• Clinical relevance: a unique cell therapy option with lower transplant reaction risk than many cell therapies, suitable for fibrotic lung disease and neuroregeneration programs.

Early Stem Cell Exosomes

High-Regenerative, CNS-Penetrant Vesicles

• Exosomes derived from early stem/trophoblast cells used instead of whole cells to enable blood-brain and blood-retina barrier penetration.
• Possess very high differentiating and regenerative potential.
• Promising outcomes for neurodegenerative diseases, including Parkinson’s disease.
• Effective in post-traumatic brain injury and cerebrovascular accident contexts.
• Potential clinical application for contact-sport–related chronic traumatic encephalopathy (CTE); strong interest for use in professional rugby players.
• Clinical relevance: a targeted, non-cellular regenerative tool for CNS and retinal indications where barrier penetration is required.

Progenitor Cells and Induced Pluripotent Stem Cells

Autologous iPSC-Derived Organ-Specific Progenitor Cells

• Organ-specific progenitor cells (kidney, heart, liver, retina) provide highest regenerative potential for respective organs.
• Workflow: patient blood banking → reprogramming with Yamanaka factors → induced pluripotent stem cells → differentiation into organ-specific progenitors.
• Reported clinical success reversing decreased GFR in kidney transplant rejection using newly generated cells.
• Cell-banking service planned for patients pursuing long-term regenerative/ longevity care.
• Clinical relevance: autologous approach minimizes immunologic issues and supports regenerative strategies aimed at avoiding organ failure interventions (e.g., dialysis).

Gene Therapies

Plasmid or mRNA – Non-Viral, Non-Integrating

• Use of plasmid or mRNA delivery to transiently express beneficial proteins without altering host genome.
• Klotho protein gene therapy highlighted as strongly correlating with reduced morbidity and mortality and described as nearing a “youth” therapeutic effect.
• Follistatin gene therapy for muscular rejuvenation and overall wellbeing.
• VEGF gene therapy to improve endothelial lining — indicated for peripheral artery disease, diabetic vasculopathy, and erectile dysfunction.
• Reports of clinical use: intranasal Klotho drops applied for head injury recovery, intramuscular injections for cognition; clinician use with positive outcomes.
• Customized gene therapies being developed for rare genetic mutations on a case-by-case basis.
• Clinical relevance: safe, non-permanent enhancement of target proteins to address vascular, muscular, and systemic aging-related pathologies.

Muse Cells

Stress-enduring, Targeted Regenerative Cells

• Multilineage-differentiating stress-enduring (Muse) cells circulate in blood and home to damaged tissue fragments.
• Detect damaged cells via sphingomyelin residues and can differentiate into the needed cell type within ~48 hours.
• Very low HLA marker expression, yielding minimal immune reactivity and lower transplant reaction risk compared with mesenchymal stem cells.
• Noted for apparent “intelligent” homing and rapid in situ differentiation for tissue regeneration.
• Clinical relevance: highly targeted regenerative option with lower immune risk for applications requiring rapid replacement of damaged cells..

NK Cell-Derived Exosomes

Natural Killer Cell Exosomes for Immune Support and Senolytic Therapy

• NK cells clear mutated, cancerous, virus-affected, and senescent cells; their exosomes retain targeting functions in a much smaller, penetrant form.
• Exosomes are millions of times smaller than cells, enabling penetration into bone and across the blood-brain barrier — relevant for metastasis control in bones and brain.
• Effective senolytic tool to reduce senescent cell burden.
• Recommended protocol: combine NK exosomes with plasmapheresis (plasma exchange) to remove debris from destroyed senescent cells; described as a “golden protocol.”
• Operational plans include mobile apheresis capability to support the protocol in-field.
• Clinical relevance: central component in rejuvenation programs addressing metastatic disease niches and systemic senescence.

Chronic Traumatic Encephalopathy (CTE)

Multimodal CTE Treatment Protocols – Inflammation Reduction and Regenerative Phase

• Target population: professional rugby players, American football players, military veterans with TBI/CTE.
• Multimodal approach includes cerebrolysin, growth-hormone–stimulating peptides, hyperbaric oxygen therapy, and intranasal/intrathecal exosomes.
• Protocol emphasis: first reduce inflammation and astrocyte proliferation, then proceed to regeneration.
• Clinical experience: extensive traumatic brain injury practice, collaboration with Veterans Affairs and medico-legal teams; medical director role at a brain-care clinic focused on TBI.
• Strategic opportunity: successful high-profile cases could deliver significant public and referral impact.
• Clinical relevance: structured, staged protocol combining anti-inflammatory measures with regenerative biologics for complex neurotrauma and CTE cases.

Novel Peptides

Advanced Peptide Library – Targeted Signaling Modulators for Organ Systems

• Knowledge base of hundreds of peptides beyond commonly known sets.
• Examples: Klotho peptide 1 and 6 (Klotho fragments) for kidney and other indications; intracellular sigma peptide for CNS regeneration (originally for severed spinal cord); VD11 for neuromuscular junction restoration.
• FOXO family peptides (FOXO3/4/6/8) modulate DNA transcription processes linked to healthy aging.
• Humanin peptides (1–10) are mitochondrial-genome–encoded signaling peptides.
• Peptide groups target fibrotic disease, mitochondrial health, and reproductive medicine.
• Over 80 peptides currently in large-company clinical trials, indicating active translational development.
• Clinical relevance: precision signaling tools to “fine-tune” physiological processes across multiple organ systems.

Sublingual and Oral Peptide Delivery

Non-Invasive Routes to Improve Adoption

• Patient preference: up to ~70% of patients reluctant to use subcutaneous injections.
• Available oral peptides include MOTS-C and tirzepatide for metabolic/weight-loss applications.
• Technologies convert peptides into small droplets or use nanostructures (lipid carriers and similar) to facilitate sublingual mucosal absorption and capillary penetration.
• Development of oral capsule forms is progressing; scale and production improvements are reducing costs and increasing feasibility.
• Clinical relevance: non-invasive delivery significantly expands patient accessibility and adherence for peptide-based therapies.